¡Ya estamos en ! Descubre más
LJPC

La Jolla Pharmaceutical Company

Excluida de cotización

LJPC dejó de cotizar en bolsa el 19 de agosto de 2022.

 

Acerca de: La Jolla Pharmaceutical Co is a biopharmaceutical company. The company's main activity is the discovery, development, and commercialization of innovative therapies that improve patients' life-threatening conditions. The company's portfolio consists of an angiotensin II formulation, which regulates blood pressure; a formulation of hepcidin, an endogenous peptide hormone that regulates iron metabolism; and an antibiotic approved by the U.S. Food and Drug Administration.

Empleados: 66

Noticias

Positivo
Neutral
Negativo
Sentimiento 3 meses
Positivo 0%
Neutral 0%
Negativo 0%

No hemos recibido artículos de noticias recientes sobre LJPC.

Gráficos de precios implementados con Lightweight Charts™